螺内酯治疗射血分数保留性心力衰竭的研究进展  

Role of Spironolactone for Treatment of Heart Failure with Preserved Ejection Fraction

作　　者：黄正林[1] HUANG Zhenglin(Department of Cardiology,The People’s Hospital of Yaan,Yaan 625000,Sichuan,China)

机构地区：[1]雅安市人民医院心内科,四川雅安625000

出　　处：《心血管病学进展》2022年第9期828-832,共5页Advances in Cardiovascular Diseases

摘　　要：射血分数保留性心力衰竭(HFpEF)是一类特殊的心力衰竭亚组,其治疗尚无标准模式。作为临床常用的抗心力衰竭药物,螺内酯可改善射血分数降低性心力衰竭患者的心室重塑及预后,但治疗HFpEF是否获益尚无共识。目前研究螺内酯治疗HFpEF常采用随机对照研究方法,内容包括利尿作用及利尿外作用、对生活质量和预后的影响及临床使用影响因素。各研究结论不一致,分析可能与研究对象选择及HFpEF病因复杂相关,也提示螺内酯应用的复杂性。现总结近几年相关研究,以期探索目前螺内酯治疗HFpEF的研究方向和临床应用效果。The heart failure with preserved ejection fraction(HFpEF) was a special subgroup of heart failure whose treatment has not yet been standardized.As a commonly used anti heart failure drug, spironolactone can improve ventricular remodeling and prognosis in patients with heart failure with reduced ejection fraction, but there is no consensus on whether the treatment of HFpEF benefits.RCT trials were used to study the role of spironolactone for treatment of HFpEF,and the contents include diuretic and extradiuretic effects, the impact on quality of life and prognosis, and the influencing factors of clinical use.The inconsistent outcomes of many trials might be related to complex baseline of selected subjects and complex etiology of HFpEF,and also indicated the complexity of spironolactone application.This paper summarizes the relevant research in recent years, in order to explore the current research direction and clinical application effect of spironolactone in the treatment of HFpEF.

关 键 词：螺内酯 射血分数保留性心力衰竭 预后 

分 类 号：R541.6[医药卫生—心血管疾病]